Impact Factor
3.64
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.50
479 total citations
h5-index
26
h5 depth signal
Cited share
83.2%
94 of 113
Total citations
479
Citation footprint
Metric signal
3.56
External metric anchor
Self-citation
13.8%
66 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
310
United Kingdom
213
Australia
115
Canada
95
Netherlands
90
Citing Fields of Research
Medical Ethics
246
Patient Care
142
Health Education & Remote Healthcare
117
Palliative Care
88
Economics
83
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,001
Articles tracked across the journal lifetime
Indexed publication set
113
94 cited publications
Last 12 months
68
5.7 publications/month
Open access share
67.6%
46 OA publications in the last year
Leading citing country
United States
310 citing publications
Leading citing field
Medical Ethics
246 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v4, 2011-
v4, 2011-
Active Coverage
Research Focus & Classification
Indexed Subjects
Medical Ethics
Palliative Care
Patient Care
Health Education & Remote Healthcare
Economics
Hematology
Broad Categories
Health Services
Health Services Research
Medical Ethics
Palliative Care
Economics
Patient Care
Health Education & Remote Healthcare
MeSH Descriptors
Clinical Trials as Topic
Outcome Assessment, Health Care
Patient-Centered Care
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s40271-026-00850-1
Open DOI
Educational Materials for Health-Related Discrete Choice Experiments: A Theory-Driven Approach
To make informed choices in health-related discrete choice experiments (DCEs), respondents need to understand the choice scenarios, alternatives, attributes and attribute levels presented to them. Respondent populations are often highly ...
02
DOI 10.1007/s40271-026-00847-w
Open DOI
Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes
There is an unmet need for effective and well-tolerated oral formulations of glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes. Orforglipron and oral semaglutide are two oral glucagon-like peptide 1 receptor...
03
DOI 10.1007/s40271-026-00848-9
Open DOI
Capturing the Lived Experiences of Informal Care in Acute Leukaemia: A Multinational Qualitative Study
04
DOI 10.1007/s40271-026-00849-8
Open DOI
Measures of Overall Illness Severity and Burden for ME/CFS: A Scoping Review
05
06
DOI 10.1007/s40271-026-00841-2
Open DOI
17th Meeting of the International Academy of Health Preference Research
07
DOI 10.1007/s40271-026-00843-0
Open DOI
Designing National Programmes for Expanded Carrier Screening: Results from a Discrete-Choice Experiment in Singapore
08
09
DOI 10.1007/s40271-026-00842-1
Open DOI
Experiences with Efanesoctocog Alfa: Exit Interviews with Caregivers of Previously Treated XTEND-Kids Phase III Trial Patients with Haemophilia A
Background Until recently, most treatments for haemophilia A consisted of regular prophylaxis with factor VIII (FVIII) replacement therapy, which, to be effective, needed to be given multiple times per week. Efanesoctocog alfa is a once-...
10
Bibliographical & Catalog Notes
Description based on first issue; title from cover.
Also issued online; subscription required for full-text online access.